Regulatory
FDA Approves First Muscle-Targeted Therapy for Spinal Muscular Atrophy
Scholar Rock’s Isembyld (apitegromab) is meant to be added on top of existing SMA drugs — attacking the disease from the muscle side rather than the nerve side.